Table 2. Summary information of all RCTs included in the network meta-analysis.
| Trial acronym | Source | Design | Population | Treatment (sample size) | Primary Endpoint |
|---|---|---|---|---|---|
| Aikawa 2013 | [49] | R/MC/Ph3/OL | Confirmed MRSA-cSSTI | DAP (n = 88) VAN (n = 22) |
Clinical and microbiological response at TOC |
| DAP-SST-98-01 and DAP-SST-99-01 |
[45] | R/MC/Ph3/SB | cSSSI | DAP (n = 534) PRP (cloxacillin, nafcillin, OXA, or flucloxacillin), or VAN (n = 558) |
Clinical response at TOC |
| DISCOVER 1 | [32] | R/MC/Ph3/DB | ABSSSI | DAL (n = 288) VAN, with an option to switch to oral LZD (n = 285) |
Early clinical response (after 48 to 72 hours of therapy) |
| DISCOVER 2 | [32] | R/MC/Ph3/DB | ABSSSI | DAL (n = 371) VAN, with an option to switch to oral LZD (n = 368) |
Early clinical response (after 48 to 72 hours of therapy) |
| Breedt 2005 | [44] | R/MC/Ph3/DB | cSSSI | TIG (n = 275) VAN + AZA (n = 271) |
Clinical response at TOC |
| Florescu 2008 | [53] | R/MC/Ph3/DB | Confirmed MRSA-cSSSI, cIAI or pneumonia | TIG (n = 118; patients with cSSSI: 83) VAN or LZD (n = 39; patients with cSSSI: 27) |
Clinical response at TOC |
| Itani 2010 | [50] | R/MC/Ph4/OL | Confirmed MRSA-cSSTI | LZD (n = 537) VAN (n = 515) |
Clinical cure at EOT |
| VER001-9 | [33] | R/MC/Ph3/DB | cSSSI | DAL (n = 571) LZD (n = 283) |
Clinical success at TOC |
| Katz 2008 | [46] | R/MC/SB | cSSSI | DAP (n = 48) VAN (n = 48) |
Clinical response at 7–14 days post-therapy |
| Kohno 2007 | [12] | R/MC/OL | Confirmed MRSA-cSSTI, pneumonia or sepsis | LZD (n = 100; patients with cSSTI: 31) VAN (n = 51; patients with cSSTI:17) |
Clinical and microbiological outcome EOT |
| Konychev 2013 | [54] | R/MC/Ph3/OL | cSSTI with or without bacteraemia | DAP (n = 81) SSP or VAN (n = 39) |
Clinical success at TOC |
| Lin 2008 | [51] | R/MC/Ph3/DB | cSSTI or pneumonia | LZD (n = 71; patients with cSSTI: 33) VAN (n = 71; patients with cSSTI: 29) |
Effective treatment rate at EOT and FU |
| Sacchidanand 2005 | [47] | R/MC/Ph3/DB | cSSSI | TIG (n = 295) VAN + AZA (n = 298) |
Clinical cure rate at TOC |
| Sharpe 2005 | [13] | R/OL | Confirmed MRSA-cSSTI | LZD (n = 30) VAN (n = 30) |
Clinical and microbiological outcomes |
| Stevens 2002 | [14] | R/MC/OL | Presumed or confirmed MRSA-cSSTI, pneumonia or urinary tract infection | LZD (n = 240; patients with cSSTI: 102) VAN (n = 220; patients with cSSTI: 108) |
Clinical and microbiological outcomes at TOC |
| Teras 2008 | [48] | R/MC/Ph3/DB | cSSSI | TIG (n = 196) VAN + AZA (n = 191) |
Clinical response at TOC |
| Weigelt 2005 | [15] | R/MC/OL | Presumed or confirmed MRSA-cSSTI | LZD (n = 476) VAN (n = 454) |
Clinical response at TOC |
| Wilcox 2004 | [52] | R/MC/Ph3/OL | cSSTI, pneumonia, right-sided endocarditis, or bacteraemia | LZD (n = 215; patients with cSSTI: 123) TEI (n = 215; patients with cSSTI: 117) |
Clinical outcome at the EOT and TOC visits |
| Wilcox 2009 | [55] | R/MC/OL | Presumed or confirmed MRSA-cSSSI or CRBSI |
LZD (n = 363; patients with cSSSI: 164) VAN (n = 363; patients with cSSSI: 151) |
Microbiologic outcome at TOC |
Abbreviations: ABSSSI: acute bacterial skin and skin structure infection; AZA: aztreonam; CRBI: catheter-related bloodstream infection; cSSSI: complicated skin and skin structure infection; cSSTI: complicated skin and soft tissue infection; DAL: dalbavancin; DAP: daptomycin; DB: double blinded; EOT: end of treatment; ITT: intent to treat; LZD: linezolid; MC: multicentre; MRSA: methicillin-resistant Staphylococcus aureus; OL: open label; OMA: omadacycline; OXA: oxacillin; Ph: phase; R: randomised; SB: single blinded; SSP: semi-synthetic penicillin; TEI: teicoplanin; TIG: tigecycline; TOC: test of cure; tx: treatment; TZD: tedizolid phosphate; VAN: vancomycin.